Robert B. Ford

New Capabilities

Leading Abbott's precision oncology expansion

Cancer patients often finish treatment not knowing whether it worked. Abbott's new Oncodetect test, launched October 26, tries to answer that question sooner. The blood test tracks up to 5,000 mutations unique to each patient's tumor and can detect cancer DNA at concentrations below one part per million.

Updated Oct 26

Money Moves

As of May 2026: Leading post-acquisition integration

Abbott Laboratories closed its $21 billion acquisition of Exact Sciences on March 23, making the maker of the Cologuard colorectal cancer screening test a wholly owned subsidiary of one of the world's largest healthcare companies. The all-cash deal, at $105 per share, passed through antitrust review without a second request from regulators—a sign of how little the two companies' product lines overlapped before this combination.

Updated May 30